Lamictal XR's Monotherapy Claim May Spur More Historical Control Trials

GlaxoSmithKline’s anti-epileptic drug Lamictal XR gained approval for conversion to monotherapy without any post-marketing commitments despite concerns about the novel trial design employed for the application.